Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $44,599.

  • bioAffinity Technologies' Depreciation and Depletion rose 10.20% to $44,599 in Q3 2025 from the same period last year, while for Sep 2025 it was $175,636, marking a year-over-year decrease of 38.55%. This contributed to the annual value of $162,332 for FY2024, which is 30.35% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Depreciation and Depletion stood at $44,599, which was up 0.29% from $44,468 recorded in Q2 2025.
  • bioAffinity Technologies' Depreciation and Depletion's 5-year high stood at $166,284 during Q4 2023, with a 5-year trough of $800 in Q3 2022.
  • In the last 3 years, bioAffinity Technologies' Depreciation and Depletion had a median value of $42,806 in 2024 and averaged $49,930.
  • As far as peak fluctuations go, bioAffinity Technologies' Depreciation and Depletion surged by 5,536.88% in 2023, and later slumped by 74.26% in 2024.
  • Over the past 4 years, bioAffinity Technologies' Depreciation and Depletion (Quarterly) stood at $7,282 in 2022, then soared by 2,183.49% to $166,284 in 2023, then slumped by 74.26% to $42,806 in 2024, then climbed by 10.20% to $44,599 in 2025.
  • Its Depreciation and Depletion was $44,599 in Q3 2025, compared to $44,468 in Q2 2025 and $43,763 in Q1 2025.